Insmed INSM Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| R&D by Product | |||||
| ARIKAYCE external R&D expenses | $41.44M-31.2% | $60.27M-3.4% | $62.42M+2.3% | $61.02M— | |
| Brensocatib external R&D expenses | $96.52M-2.1% | $98.57M-9.2% | $108.56M+5.9% | $102.53M— | |
| INS1148 | $40M— | $0— | $0— | —— | |
| Other external R&D expenses | $129.87M+43.3% | $90.6M-31.7% | $132.65M+288% | $34.2M— | |
| TPIP external R&D expenses | $94.2M+42.9% | $65.94M+31.4% | $50.19M+28.0% | $39.22M— | |
| Product revenues, net by Geography | |||||
| International | $153.47M— | —— | $81.01M— | —— | |
| US | $452.95M+77.8% | $254.8M+13.7% | $224.2M+20.5% | $185.99M+16.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insmed break its business down?
- Insmed (INSM) reports r&d by product across 5 parts — ARIKAYCE external R&D expenses, Brensocatib external R&D expenses, INS1148, Other external R&D expenses and TPIP external R&D expenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Insmed's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insmed's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
